SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Event: mTOR Signaling Dysregulation in Progressive Supranuclear Pal

event 1,074 words KG: mTOR 2026-03-23

kind:event section:events state:published

Contents

mTOR Signaling Dysregulation in Progressive Supranuclear Palsy

Knowledge Graph

Related Hypotheses (30)

APOE-Dependent Autophagy Restoration
Score: 0.61 ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro
Score: 0.66 SASP-Mediated Complement Cascade Amplification
Score: 0.70 TREM2-Dependent Microglial Senescence Transition
Score: 0.69 Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.67

Transcriptional Autophagy-Lysosome Coupling
Score: 0.66 Digital Twin-Guided Metabolic Reprogramming
Score: 0.61 Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59 SASP-Driven Aquaporin-4 Dysregulation
Score: 0.59 Circadian-Synchronized Proteostasis Enhancement
Score: 0.58 Microbial Inflammasome Priming Prevention
Score: 0.58 AMPK hypersensitivity in astrocytes creates enhanced mitocho
Score: 0.57 SASP-Mediated Cholinergic Synapse Disruption
Score: 0.56 Purinergic Signaling Polarization Control
Score: 0.55 Circadian Clock-Autophagy Synchronization
Score: 0.55 Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54 Phase-Separated Organelle Targeting
Score: 0.52 Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52 Membrane Cholesterol Gradient Modulators
Score: 0.52 Heat Shock Protein 70 Disaggregase Amplification
Score: 0.51 Astroglial Gap Junction Coordination via Connexin-43 Phospho
Score: 0.50 Autophagosome Maturation Checkpoint Control
Score: 0.49 Lysosomal Calcium Channel Modulation Therapy
Score: 0.49 Orexin-Microglia Modulation Therapy
Score: 0.49 TREM2-mediated microglial tau clearance enhancement
Score: 0.49 Metabolic Switch Targeting for A1→A2 Repolarization
Score: 0.48 Circadian Rhythm Entrainment of Reactive Astrocytes
Score: 0.48 Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.48 APOE-TREM2 Interaction Modulation
Score: 0.48 Metabolic Circuit Breaker via Lipid Droplet Modulation
Score: 0.48

Related Analyses (30)

4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived

APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived Synaptic pruning by microglia in early AD
neurodegeneration · archived Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived Epigenetic reprogramming in aging neurons
neurodegeneration · archived Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived Does TFEB dysfunction cause neurodegeneration or represent a
neurodegeneration · completed Extracellular vesicle biomarkers for early AD detection
neurodegeneration · completed Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed

Related Experiments (22)

s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40 Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40 ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40 ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40 Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40

Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40 Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40 Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40 Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40 C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40 Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40 FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40 Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40 N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40 Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40 Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40 Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40 Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40 PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40 Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40 TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40 Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40

See Also (5)

ABCG2 (BCRP) - ATP Binding Cassette Subfamily G Member
gene · KG edge: therapeutic_target ABCG1 Gene
gene · KG edge: inhibits ABCB1 (MDR1) - ATP Binding Cassette Subfamily B Member
gene · KG edge: therapeutic_target ABCA1 - ATP-Binding Cassette Transporter A1
gene · KG edge: activates AMPK (AMP-Activated Protein Kinase)
entity · KG edge: activates

Knowledge Graph (12 edges)

mTOR activates Autophagy

mTOR interacts_with Autophagy

mTOR implicated_in neurodegeneration

mTOR activates PPARG

mTOR activates MAP1LC3B

mTOR activates RPS6KB1

mTOR activates PPARA

mTOR activates PIK3C3

mTOR activates RUBCN

mTOR activates LRP2

SciDEX — scidex.ai — Dashboard | Atlas